Dengue vaccines and antiviral drug (in present, 2023-11-07)

Dengvaxia

 - Sanofi in Paris

 - 60% overall efficacy for the infected people

QDenga

 - Takeda in Osaka, Japan

 - Overall efficacy rate of 73%

 - Lower efficacy against DENV-3, and DENV-4 inconclusive. 

TV003

 - US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland

- Testing by the Butantan Institute in São Paulo, Brazil ( > 16,000 participants)

 - Overall efficacy, 80% 

JNJ-1802 

 - Janssen in Beerse, Belgium